Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy is a research paper published in Journal for ImmunoTherapy of Cancer (2022). On theSindex it has a DataRank of 0. It has been cited 50 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Welch Foundation
Grant: AU-0042-20030616
U.S. Department of Defense
Grant: BC151081
U.S. Department of Defense
Grant: LC200368
Cancer Prevention and Research Institute of Texas
Grant: RP150551
Cancer Prevention and Research Institute of Texas
Grant: RP190561
National Cancer Institute
Grant: R01CA101795
National Cancer Institute
Grant: R01CA246547
National Cancer Institute
Grant: U54CA210181
National Institutes of Health
Grant: 5R01CA246547-03
CD4+ T cells and neoantigens in melanoma immunotherapy.
National Institutes of Health
Grant: 7R01CA101795-13
NOVEL STRATEGIES FOR INTERVENTION OF INFLAMMATORY DISEASES AND CANCER
National Institutes of Health
Grant: 5U54CA210181-05
Center for Immunotherapeutic Transport Oncophysics
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals